Reviewing Myovant Sciences (MYOV) and Peregrine Pharmaceuticals (CDMO)

Myovant Sciences (NYSE: MYOV) and Peregrine Pharmaceuticals (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Myovant Sciences and Peregrine Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Peregrine Pharmaceuticals 0 0 1 0 3.00

Myovant Sciences currently has a consensus price target of $22.50, indicating a potential upside of 67.16%. Peregrine Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 198.51%. Given Peregrine Pharmaceuticals’ higher possible upside, analysts plainly believe Peregrine Pharmaceuticals is more favorable than Myovant Sciences.

Valuation & Earnings

This table compares Myovant Sciences and Peregrine Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$83.44 million ($1.41) -9.55
Peregrine Pharmaceuticals $57.63 million 2.63 -$28.15 million ($0.81) -4.14

Peregrine Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Peregrine Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Myovant Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Insider and Institutional Ownership

79.2% of Myovant Sciences shares are owned by institutional investors. Comparatively, 18.4% of Peregrine Pharmaceuticals shares are owned by institutional investors. 3.0% of Myovant Sciences shares are owned by insiders. Comparatively, 2.5% of Peregrine Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Myovant Sciences and Peregrine Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -53.75% -48.90%
Peregrine Pharmaceuticals -39.23% -52.55% -24.77%


Peregrine Pharmaceuticals beats Myovant Sciences on 8 of the 12 factors compared between the two stocks.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Peregrine Pharmaceuticals Company Profile

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply